Ribociclib

Common brands: Kisqali, Femara, Letrozole, Faslodex, Cligavyx

Top reporter: Novartis Pharmaceuticals Corporation

Aromatase Inhibitor [EPC]Estrogen Receptor Antagonist [EPC]RANK Ligand Inhibitor [EPC]Kinase Inhibitor [EPC]Nonsteroidal Anti-inflammatory Drug [EPC]
30,043
Total Reports
23,080
Serious Reports
4,504
Death Reports
30
Reported Reactions
Death Report Ratio: High (14.99%)

Patient Demographics

Male
418
Female
27,546

Reported Adverse Reactions (30)

Side effects reported in FDA adverse event reports for Ribociclib.

# Reaction Reports % of Total
1 NEUTROPENIA 3,858
7.5%
2 NAUSEA 3,653
7.1%
3 FATIGUE 3,619
7.0%
4 MALIGNANT NEOPLASM PROGRESSION 2,637
5.1%
5 DEATH 2,475
4.8%
6 VOMITING 2,067
4.0%
7 DIARRHOEA 1,988
3.9%
8 WHITE BLOOD CELL COUNT DECREASED 1,861
3.6%
9 PAIN 1,791
3.5%
10 METASTASES TO BONE 1,687
3.3%
11 BREAST CANCER METASTATIC 1,568
3.0%
12 DYSPNOEA 1,558
3.0%
13 ASTHENIA 1,550
3.0%
14 MALAISE 1,538
3.0%
15 ANAEMIA 1,471
2.9%
16 LEUKOPENIA 1,390
2.7%
17 ALOPECIA 1,366
2.6%
18 DECREASED APPETITE 1,356
2.6%
19 ARTHRALGIA 1,334
2.6%
20 PRURITUS 1,301
2.5%
21 HEADACHE 1,276
2.5%
22 RASH 1,273
2.5%
23 COUGH 1,215
2.4%
24 DIZZINESS 1,204
2.3%
25 ELECTROCARDIOGRAM QT PROLONGED 1,113
2.2%
26 PYREXIA 1,094
2.1%
27 CONSTIPATION 1,091
2.1%
28 DRUG INEFFECTIVE 1,090
2.1%
29 PAIN IN EXTREMITY 1,069
2.1%
30 METASTASES TO LIVER 1,055
2.0%

Important Disclaimer

FDA adverse event reports are submitted voluntarily and do not prove causation. A reported reaction does not mean the drug caused it. Drugs with more users naturally have more reports. Always consult your doctor or pharmacist before making medication decisions.